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~ Plasma Brain Netrluretlc Peptlde Levels Increase 
in Proportion to the Extant of Right Ventrleular 
Dysfunction In Pulmonary Hypertension 
N. Nagoya, T, Nlshlklml, Y, Oknno, M, Uematsu, T, Batch, S, Kyotanl, 
S, Kurlbayashl, K, Keng~wa, National Cardiovascular Center, Osaka, dapnn 
B~ckgrOund: Plasma BNP Is known to Increase In proporllon to the degree 
of left vontficular (LV) overload. However, whether brain natrluretlc peptlde 
(BNP) secretion is also regulated in the presence of right ventrlcular (RV) 
ovedoed remains unknown, This study sou0hf to Investigate the Influence 
of RV hemodynemlcs and function on the secretion of BNP in patients with 
Isolated RV overload, 
Methane: Plasma BNP and atrial nntrluratlo peptldo (ANP) levels in the 
pulmonary artery wora measured In 44 patients with RV overload', RV volume 
overload (RVVO) due to atrial aeptal defect (n ,, 18) end RV pressure overload 
(RVPO) due to pdm~Iry or thremboemboll¢ pulmonary hypertension (n .  20), 
Right hear1 catheterization wee performed tn ell patients, RV and LV ejection 
fraetlon, myocardial mass, and volume of the 4 chambers were determined 
,,sing electron beam computed tomogmphy, 
Re.~utta: Though both plasma BNP and ANP were slgnlflcently elevated 
In RV ovodoad compared with control sublects, plasma BNP and BNPIANP 
ratio were significantly higher In RVPO th~n In RVVO (BNP', 294:1 72 vs, 
48 ;I 14 pg/ml, BNP/ANP: 1,6 :t 0,2 vs, 0,8 ~ 0,9, p ~ 005, respectively), 
Plasm~ BNP positively correlated with mann pulmonary arterial pressure (r 
0,73), total pulmonary resistance (r ~ 0,Tg), mean fight atrial pressure (r 
0,Tg), RV end.diastolic pros~,lro ( r .  0,70), and RV myocardial mass (r - 
0,71); negatively correlated with cardiac output (r = 0,33) and RV ejection 
fraction ( r .  0,71), Plasma BNP significantly decreased from 315 t 120 to 
144 • 54 pg/ml by long term vasodllator therapy (total pulmonary resistance 
decreased from 23 ~ 4 to 15 ~:~ 3 Wood units), 
Conclusions: Plasma BNP levels increase in proportion to the extent of 
RV dysfunction In pulmonary hypedonslen. 
~ Therapeutic and Limitation of  Human Effects 
Atrial Natriumtlc Peptlde in Patients With 
Congestive Heart Failure 
H, Watanabe ~ , M, Kakthana, S, Ohtsuka, Y, Suglshlta. ~KINU Medical 
A.qsoctMton Hospital, MIt~ukaldo, Japan: University of Tsukut~l, Tsuku~l, 
Japan 
Backgro~md: Alpha human atrial natrlumtlc poptide (ANP) Is available as a 
therapeutic agent for congestive heart failure. Continuous adminiMratton of 
ANP has L'oen reported to induce the attenuation of hemodynamic effects in 
patients with congostLve head failure due to dounregulatlon of ANP receptors. 
This study was designed to elucidate the relationship between levels of 
endogenous ANP and therapeutic effects of exogenous ANP. 
Methods: Fourteen patients with congestive head failure were divided tote 
two groups on the basis of baseline level of endogenous ANP (pg/ml) (high 
group: c250, n = 7; low group: ..250, n = 7). After baseline measurements 
were obtained, dose titration was stared by infusing ANP at a rate of 0.05 
I=glkglmin, After achieving the desired hemodynamlc response (30% reduc- 
tion of putmonary adory pressure), the infusion rate of ANP was maintained 
for 24 hours. Measurements of hemodynamic parameters and blood sam- 
piing were pedormed serially at the baseline, 6, 12, 18, and 24 hours after 
the infusion, 
Results: At the baseline, moan pulmonary artery pressure (PA, mmHg), 
mean pulmonary capillary wedge pressure (PCWP, mmHg), and plasma 
cGMP level were comparable in the two groups, At 6 hours after the infusion 
of ANP, PA and PCWP were significantly decreased (high group: PA, 47 .~: 
6 to 33 ± 5; PCWP, 23 *. 6 to 15 :~ 4; low group, PA: 45 ± 8 to 32 ± 6; 
PCWP: 24 ± 8 to 16 ~ 5), and plasma cGMP (pmol/ml) was signiticantty 
increased (high group, 8 i 3 to 39 ~: 11; low group, 3 ~: 2 to 44 :~ 13). 
However, at 12 hours, in the high group, PA (39 ~- 11) and PCWP (21 t: 5) 
were significantly elevated (p -: 0.05 vs at 6 hours) and plasma cGMP (14 
:~- 6) was significantly decreased (p < 0.05 vs at 6 hours). In contrast, in the 
low group, the effects on PA (29 :~: 5), PCWP (17 ~ 4) and plasma cGMP 
(39 t: 11) were maintained at 12 hours. 
Conclusion: ANP is a potentially useful therapeutic agent for congestive 
heart failure in patients with low level of endogenous ANP, But the effects 
may be attenuated in patients with high level of endogenous ANP during 
continuous administration of ANP. 
~ Infusion or  Co- infus ion of  Brain Natrluretic 
Peptlde And/or Adrenomedul l in in Human Heart 
Failure 
J.G. Lainchbury, AM. Richards, M.G. Nicholls, E.A. Espiner, T.G. Yandte. 
Christchurch Hospital, Christchurch, New Zealand 
In random order, placebo controlled, studies we gave 4 I~our (hi infusions of 
Brain Natrluretlc Peptlde (B) (3.0 pmol/kg/mln), Adrenomedultln (A) (2.65 end 
5,3 pmol/kg/min; 2 h each) or both combined (C) to 6 males with congestive 
heart failure (CHF, left ventficutar ejection fractions <35%). Blood pressure 
(BP) fell with B, A and C (peak falls: systolic 10, 20 end 23 mmHg end 
diastolic 8, 17, 19 mmHg respectively, p -~ 0,01 for all), Heart rote Increased 
with A and G (peak increase 13 bpm for both, p .~ 0,01), Plasma B increased 
with B end C (peak Increase 00pmol/L for both, p < 0,01), A was Increased 
by A end C (peak Increase 60 pmot/L for both, p < 0,01). Atdal netfiumttc 
pepUde, eplnephfine and cortisol were unchanged, Noreplnephrlna (NE) wee 
Increased by B, A end C (peek rise 650, 1103, end 1403 pmol4 ret=pectlvely, 
I,e, by 31.-66%, p ~- 0,01), Renln was unchanged by B but Increased by A 
nnd C (peek rise 320 and 2g0%, p < 0,01) whilst aldostomne was elmtlar 
on each day, Sodium excretion Increased with B and C (peak Increase t2,8 
end 10,9 mmoll4 hre respectively, p .: 0,05 for both), A, B end C Infusions 
causecl significant decreases In BP (the greatest with A end C). Increases 
in heart rate, NE and rentn o~urmd durlilg A and C Infusions, but only NE 
mac with B, The expected aldostemna response to meier tnc~see in renln 
was blocked by A, B (but not A) had e significant natfiurobo effect which 
was presented with C despite n marked fall in BP, Co.augmentatton of Brain 
Natrlurelle Peptldo and Admnomedullln systems has unique hemodynamic 
effects In human CHF, 
~ enhan©oment of Renal 11-/3-Hydroxysterold 
Oehydrogenen A©tlvlty In Chronic  Heart Failure 
andEseentlel Hypertension 'freatecl With 
ACE-inhibit ion 
D, Dupmz, M, De Buyzoro, M, Paellnck, J,.M, Kautman, R. Rubens, 
D, Clement, Uatwrslty Hospital. Gent, Belgium 
Background: ACE-Inhibition Is a currant treatment for born chron¢; imact fail- 
ure (CHF) and essential hypertension (EHT), Steroid metabolism is known 
to be Intedemd with by chronic ACE.Inhibition and may lead to the so called 
steroid escape phenomenon, We tested the hypothesis whether chronic ACE- 
inhibition differently influences codisone/codisot excretion due to activation 
of renal 11,# hydmxystorold ehydregenase, 
Methods: Thirteen patients (71 4:6 year~) with chronic heart failure (CHF, 
NYHA class ff, ejection fraction 32 ± 13%) under a stable therapy with 
captopril tOO mg/d and furesomldo 40 mg/d wore examined together with 7 
patients (61 ± 6 years) with essential hypedension (EHT) treated with cap- 
topfi150 mg/d for at least 3 months. 24 Hours urine (U) was collected for the 
determination of cedisone (1) and cortisol (2) metabolites and their ratio using 
HPLC chromatography as well as blood sampling for the renin-angiotenstn- 
aldosterene system in supine position. 
Results: 
Plasm~ CHF EHT 
Ronln(.U/ml) 95r t 1479 120 t 117 P- O001 
Angtotonstnll(pglml) 34.2 ~ 277 21.1 * 114 P OO1 
Atdostorono (ng/dl) 189 ~ 13.4 11 2 t 9 1 P 0 05 
U.conisono (1) flag'S4 h) 64 ~ 36 39 t 25 P • 0.01 
U-cortisot(2) (1~g!24 hi 33 t: 21 30 : 19 N5 
(1)!(2) ratio 2.10 t 0,76 1.51 t 116 P - 0.05 
Conclusions: In essential hypertension and chronic head failure under 
chronic ACE-inhibition there is a steroid escape phenomenon which is sig- 
ntflcanUy greater in the head failure process. The higher cortisone/cortisol 
ratio in chmnlc heart failure under ACE-inhibition suggests a morn enhanced 
renal 11-/¢ hydrexystemid ehydregenase activity in chronic heart failure. 
~ Anglotens ln  Converting Enzyme Delet ion 
Polymorphism Does Not Increase the Risk of 
Heart Fai lure 
D.M. McNamare, M,K. Trest, A.D. Palmer, M Rudy, R.J. Alvarez, Jr., 
WD. Rosenblum. G.A, MacGowan, S. Murali, A,M. Feldman, University of 
Pittsburgh Medical Center, Pittsburgh. Pennsylvania. USA 
Backgreund: The role of the deletion allele of the angiotensin converting 
enzyme (ACE "D") as a risk factor for the development congestive heart 
failure remains controversial. In this case control study we sought to evaluate 
the hypothesis that the deletion allele would be increased in prevalence in a 
heart lailure population, when compared to age matched controls. 
Methods: r)NA was isc, latsd from whole blood and ACE genotyping per- 
formed on a series of 212 patients (P) with congestive heart failure referred 
to the Head Failure service at the University of Pittsburgh (M/F 160/52, age = 
55.3 ~ 7 11.4). These were compared to a series of 124 controls (C) without 
any history of heart failure or coronary disease (M/F 74150 age = 54.7 ± 
10.2) 
Results: The frequency of homozygotes for the insertion allele (11), het- 
erozygotes (ID), or homozygotes for the deletion allele (DD), did not differ 
between patients and controls as is displayed by the table below. 
JACC Fehn,a~, I¢F)8 AIISTRA('I'S ~ P~,,tcr 157A 
OO IO II 
P 283% 509% 20 8% 
G 258% 532% 21% 
Conclusion: This case cOntrol study suggests that the ACE delehon poly- 
morphism Is not a risk factor for the development of congestive heo~ failure, 
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~ Atonms~;tln RMr~ory Hyl~mholnt~mlemla for 
In Hemt'It, lnsplant Pallents 
J,A Kobashlgawa, JD  Mo~;I~hL TK, Ro. K, Emhom, J,D, Cassem, 
M,A, Hamillml, A~ Hago, N Kawata, H. L~ks. UniversdyotCatitorn~. Los 
A~ CA, U~ 
Hyparcholeste~la is common after heart transplant and may be assocl. 
ated with the deser t  of transplant comnaw adew disease. The use of 
HMG.CoA redu~ase inhiblfom (HRI) in head transplant patients has demon- 
strafed eft~::acy in cholesterel Iowenng; however, there is concem of myOSdks 
and d ~ i s  with HRI in head ~ t  patients on cyctosponne. AS 
them are pa~ts  Mdt rehactow to ~ HRI thmapy, attention has lumed 
toward ato~astatm which ks a new HRI and ~rs  to he morn effective 
in cholesterol Iowenng and has reported ~ fowenng. Twenty-e~ght 
heart lransplant patients at an average of 42 months after heart tran~nt, 
refracton! to pmvmus HRI therapy, were ~ to ato~astatin t0 mg Ix) q 
d. There was a s~nificant reductmn after 3 months el therein, in total choies. 
terel (269 ± 48 to 220 ± 45 mg/cB, p = 0.01) and LDL cholesterol (145 ± 42 to 
121 ± 34 mg/dl, p ~ 0.0~). TnglycerKJe levels ten(leO to be lower (330 ± 163 
to 303 ± 199 moJdl), and them dKI not appear to be an appreciable change 
in HDL cholesterol (40 ~ 16 to 38 ± 13 mojdl). There were no sy.~Jiurss of 
myos~s and no d ~ i s  with creatine kinase levels unchanged at 3 
months (97 ± 61 to 99 ± 67 moJdl). 
Conclusion: The use of the new HRI. atorvastatin, appears safe and 
eftecbve in the short term for cholesterol Iowenng in heart transplant patients 
refraCton/tO other HRI. 
• Elfect Trabecular Bone Loss After of  Cslcitriol on 
Cardiac Transplantation 
C. Wemer, T Assure. S. Echller. B. Me~ser. C.E. Angermann. R. Gartner. 
W. Rambeck, K. Theisen, H.-U. Stempfle. Untversi~, of Munich. Germany 
Background: Accelerated bone loss is well recognized comp!¢atien affer 
cardiac transplantation (HTx) due to glucocort~'o~d and cyctospanne therapy. 
The puq:~se of this prospective randomized placebo-centre!led eubie-blind 
study was to investigate the effect of Calcitnol in the prevention of bone loss 
after cardiac transplantation. Basic therapy included calcium 1000 n~j dally 
and testosterone substitution in hypogonadal patients. 
Methods. 88 male patients (moan age: 49 ± 9 yrs.. 30 ± 30 months post 
HTx) and 16 female patients (mean age: 46 ± 12 yrs.; 35 ± 28 months pa-'~t 
HTx) were randomized to 0,25 l~g Catcitnol or Fiacebo. Bone mineral density 
(BMD, g/cm~; Z-score, %) was measured at the lumbar spine w~th DXA 
(Hotogic QDR 1000) at baseline and after 12 months. Vertebral fractures 
were assessed by X-rays. 
Calcnriol (1 ,~ 25(OH)2D3) Placebo 
Baseline 12 month Basel~e 12 month 
male patients BMD [g/cm 2] 0.941 0.960 0 C.24 0929 
Z-Score [%] 91 90 89 90 
Fractures 3 3 3 3 
female patients BMD [g;cm 2] 0862 0.907 0 886 0 865 
Z-Score [%] 92 96 93 94 
Fractures 1 1 1 t 
Results: Osteoporosis therapy including calcium and testosterone sub- 
stitution in patients with hypogcnadism improves bone mass after cardiac 
transplantation. Additional replacement doses of calcitriol demonstrates no 
signilicant extra benefit regarding bone mineral density and fracture rate. 
Calcitriot revealed only a mild beneficial effect in a subgroup of patients (n 
= 23) early after cardiac transplantation (4.2 :~ 2.3 months post HTx) with a 
Z-score increase of 3.4% vs. 0.3% in the placebo group. 
• Effect of Felodiplne Versul  Diuretics on Left 
Ventricular Hypert rophy In Orthotopic Hur t  
1Yansplant Recipients 
J. Schwlftor. T DeMarco, S Gtobits, H Sakuma, C Khnsk,, K Chatterje~, 
W.W Pa,mlny, CB Htggms University of C#ltfom~t San Frano.s¢o, San 
Fr~nosco~ 04, USA 
Background: Tho potential of antittylmrter~tves to ieduc~ regres~ of left 
vefllncular hypedrophy (LVH) deperK~ not only on blood pressure cont~0t 
but may bo modulated by neurehumoml adaptation and, in ~ heart 
transplant (OH'r) recq[~l~lta, it may lnterlem with ¢y¢lospanne (Co.k) me~. 
Purpose: Compare the effect of tl~ calcium ¢~lannel bk:)cker fefo¢l~l~ 
(Fell versus diumfCs (Oiu) on LVH, neurohumorsl responses and mterect~¢~ 
with CsA. 
Methods: Twenty4wo patmnta (2 rues after OHT) and 10 heafthy eubjecm 
(age/so~ matched) were e,,amined using Mill (1,5T, GE), LV ~me~,  LV 
masa (Simpaon'a rule) and ~mctmnal pammaters were calculated tram ~r~ 
gredient echo 8hen alia images (TRTE 25/'/ms), Men@or=at end,systol~c 
waJ! stress (Sea) was also ealcglatl~(I t.~ng dlCfOll¢ notch pressure (gk~rlved 
from camlid pulse tracings). In addition, plasma nompmephnn, el~nq~nn 
(EI~), m~J plasma mnin actwlty (PRA) were measured. During 4 mos Of treat- 
ment. for each patient average CsA level and average syslolic and dmstal¢ 
blood pressures (SBP, DBP) were obtained from repa~bve mea~uremems. 
At follow up, blood work and MRI were repeated (n : 19). 
Re~Julls: At besefine, LV mass in patients was i~creesed (p .  0.o02) and 
See was reduced (p -: O001 ) remus contmt~ i~dicafing excess hypertreohy. 
Heart rate, SBP, OBP, LV eiectKm ~act;'on, and Sea were mlar  fo~ both 
groups and ¢1~ not change dunng either ~ t  (2-way ANOVA), LV 
mass decreased dunng Fel treatment and in~,ed  with Diu (~ 'mg 
interaclmn: p < 0.0001. 2.way ANOVA) In the Diu group, changes in LV 
mass were posilwely conetatad wilh PRA and EI~ at follow-up and wdh 
average CsA levels (st~atmse regression). In the Fel group, cringes in LV 
mass were correlated with SBP. but not with PRA, Ep~ and CsA. 
Conclusions: In hearts wrth mlCeSS hypertrophy, Fel induced r e ~  of 
L'~H whereas Diu could not prm~nt a further increa~.e m m.~ss. This increase 
in mass was related to neurehumoral responses and CsA. The effect of CsA 
on LV mass may be alle~uated by FeL 
~ O r a i  Ganciclovlr  Pmphyiaxis  Redtmes 
Cylomegalovirus Disease During the First Year 
After ~a, - t  Transplantation 
G.M. Mullen. M.A Silver, C.E. Lawless, J. Mendaz, P.C. Barath, 
K Malinowska. B.A. Ptsanl, P.J. O'Keefe. JA  Robinson. V Yeldandi. Loyola 
Unmers~ of ChK:acjo, Heart Transplant P~."gram. Maywood. Illin~s, USA 
Cytomegalowrus Dmease (CMVD) leads to addito~al hospdatizations and 
morbidiW after heart transplantation. Our eadier CMVD prophylaxis r~men 
had been s~;quential intmveneous Ganc~clowr fer 14 days followed by 90 
days of oral Acyctovir (Group I) versus our current strategy of 14 days of 
intravenous Ganc~cto,,nr followed by 90 days of oral Ganoictovir (Group II). 
Group I iN = 77) Group 11 (N = 35) 
Sex 55 Male.r22 Female 27 Male/B Fen~le 
Age (yearsi 498 ~ 11 6 52. I ~ 12.8 
Serology NI CMVD All CMVD 
DOnor ~ 1Recipient • 24 14 (58%) 10 0 (0%) 
DOnor +,'Reop~nt 14 2 (14%) 6 2 (33%) 
DOnor /Recu~ent. 30 3(10%) 13 0(0%) 
DOnor /Reop~ent 9 I (11%l 6 0 ((Y%,) 
Total 20126 0%i 2 (5 9%l" 
One Year Patient Survival 66 (857%) 32 (91 4%)' 
Hospital Length o! Stay Index 0.948 0.248" 
"p. 0.01 
Conclusions: The combined sequential use of intravenous/oral Gano- 
clovir is more effective prophylaxis CMVD after cardiac trensplantabon than 
intravenous Ganctctovirloral Ac'yclovir, Hospital days due to CMVD are re- 
duced by intravenous/oral Ganciclovir significantly. 
~ Lipid Treatment and Survival After Heart 
Transplantation 
C.M. Ballantyne, B.C. Short, R.C. Bourge, H.J. Eisen, DP. Fishbein, 
S.H. Kubo, K.D. Lake, B. Badovancevic, D.O. Taylor. H.O. Venture. 
C.W. Yancy, Jr., J.B. Young. Baylor College of Medicine. Houston, TX. USA 
Background: The risks and benefits of lipid-lewenng therapy atler heart 
transplantation remain poorly defined, but one nonblinded, randomized, sin- 
gle-center trial has shown significant reduction in mortality with stalin ther- 
apy. 
